Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

In collaboration with the North American Consortium for Histiocytosis (NACHO), Melissa Hines and Kim Nichols are running a clinical trial investigating the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for children with newly diagnosed or relapsed/refractory HLH. The protocol is now open at 10 participating sites, including:
 

• St. Jude Children’s Research Hospital – Memphis, TN
• Children’s Hospital of Philadelphia – Philadelphia, PA
• UCSF Benoiff Children’s Hospital – San Francisco, CA
• Children’s Hospital of Orange County – Orange , CA
• Phoenix Children’s Hospital – Phoenix, AZ
• Atrium Health Levine Children’s Hospital – Charlotte, NC
• Children’s National Medical Center – Washington, DC
• Children’s Wisconsin – Milwaukee, WI
• Cohen Children’s Medical Center – New Hyde Park, NY
• Johns Hopkins – Baltimore, MD

You can find more information about the study on the attached flyer and at: HLHRUXO clinical trial or at: https://clinicaltrials.gov/ct2/show/NCT04551131?term=ruxolitinib&cond=HLH&draw=2&rank=3

We are excited to finally have this study open and are willing to address any questions that you or your colleagues might have. Please contact us at: HLHRUXO@stjude.org

Please feel free to refer your patients to St. Jude for or to any of the above centers for potential enrollment.